{"id":722347,"date":"2026-04-17T17:20:13","date_gmt":"2026-04-17T14:20:13","guid":{"rendered":"https:\/\/buradabiliyorum.com\/en\/onward-medical-raises-e40-6m-to-advance-its-spinal-cord-stimulation-implant\/"},"modified":"2026-04-17T17:20:13","modified_gmt":"2026-04-17T14:20:13","slug":"onward-medical-raises-e40-6m-to-advance-its-spinal-cord-stimulation-implant","status":"publish","type":"post","link":"https:\/\/buradabiliyorum.com\/en\/onward-medical-raises-e40-6m-to-advance-its-spinal-cord-stimulation-implant\/","title":{"rendered":"ONWARD Medical raises \u20ac40.6M to advance its spinal cord stimulation implant"},"content":{"rendered":"
\n

The Eindhoven neurotechnology<\/a> company is using the proceeds to fund its Empower BP pivotal trial, which tests whether its implantable ARC-IM\u00ae system can treat blood pressure instability after spinal cord injury, while expanding commercial rollout of its already-cleared ARC-EX\u00ae external therapy system. Cash runway now extends to Q1 2028.<\/em><\/p>\n\n

ONWARD Medical<\/span><\/a> has raised \u20ac40.6 million in gross proceeds through an accelerated bookbuild private placement with institutional investors, the Eindhoven-based neurotechnology company announced on 16 April 2026. <\/span><\/p>\n

The transaction was anchored by a \u20ac25 million investment from <\/span>EQT Life Sciences<\/span><\/a>, with additional participation from long-only and sector-specialist investors. A total of 13,520,254 new ordinary shares were issued at \u20ac3.00 per share. <\/span><\/p>\n

The company\u2019s shares trade on Euronext Brussels, Amsterdam, and Paris under the ticker ONWD, with US ADRs on OTCQX as ONWRY.<\/span><\/p>\n

\n
\n
<\/div>\n

<\/p>\n

\n

The \ud83d\udc9c of EU tech<\/p>\n

The latest rumblings from the EU tech scene, a story from our wise ol’ founder Boris, and some questionable AI art. It’s free, every week, in your inbox. Sign up now!<\/p>\n<\/div>\n<\/div>\n<\/div>\n

ONWARD is allocating the proceeds across four uses: 40% toward development of the investigational ARC-IM\u00ae implantable system, including clinical studies and regulatory work; 30% toward expanding sales and commercial operations for the ARC-EX\u00ae system in the US, Europe, and select other markets; 20% toward quality and administrative functions; and 10% toward working capital, general<\/a> corporate purposes, and servicing existing debt.\u00a0<\/span><\/p>\n

Combined with existing cash, the raise extends the company\u2019s runway into Q1 2028, assuming no drawdown on its debt facility.<\/span><\/p>\n

The two products at the centre of this raise represent successive stages of the company\u2019s clinical programme. The ARC-EX\u00ae System, an external, non-invasive spinal cord stimulation therapy, is already commercially cleared in the United States and Europe. <\/span><\/p>\n

It delivers electrical stimulation to the spinal cord through surface electrodes, activating neural circuits below the injury to improve voluntary motor function. <\/span><\/p>\n

The ARC-IM\u00ae System takes the same therapeutic principle deeper: it is an implantable device that delivers stimulation directly, which ONWARD expects will provide more precise and effective treatment across a range of indications including blood pressure instability, bladder function, and, when paired with a brain-computer interface and AI, thought-driven movement restoration.<\/span><\/p>\n

The Empower BP pivotal trial, now the primary use of the development funding, is investigating ARC-IM\u00ae\u2019s ability to treat orthostatic hypotension and autonomic dysreflexia, dangerous blood pressure conditions that are among the most debilitating secondary complications of spinal cord injury. <\/span><\/p>\n

The trial received FDA Investigational Device Exemption app<\/a>roval in August 2025. It is randomised, double-blinded, and sham-controlled, the gold standard for medical device pivotal trials, and is expected to involve approximately 20 leading neurorehabilitation and neurosurgical research centres across the US, Canada, France, Germany, Spain, and the UK. <\/span><\/p>\n

The first participant was enrolled and implanted in Q1 2026 at Craig Hospital in Denver, Colorado, and 10 sites are now actively recruiting.<\/span><\/p>\n

ONWARD holds 10 Breakthrough Device Designations from the US FDA, a status granted to devices that provide more effective treatment for serious conditions where no adequate alternatives exist. <\/span><\/p>\n

This designation accelerates the FDA review process and provides more frequent interaction with the agency during development. <\/span><\/p>\n

CEO Dave Marver described the raise as validating both the commercial trajectory of ARC-EX\u00ae and the clinical potential of ARC-IM\u00ae: <\/span><\/p>\n

\u201cThe strong support from EQT and other high-quality investors underscores the rapid adoption of the ARC-EX\u00ae System and validates our successful transition to a commercial-stage organization.\u201d<\/em><\/span><\/p>\n

Stifel Europe Securities SAS acted as Sole Global Coordinator, with Bank Degroof Petercam SA\/NV serving as joint bookrunner alongside Stifel. <\/span><\/p>\n

The new shares are expected to be listed on 20 April 2026. The company, EQT, and certain board members have agreed to a 90-day lockup on the shares.<\/span><\/p>\n<\/p><\/div>\n

If you liked the article, do not forget to share it with your friends. Follow us on\u00a0Google News<\/a><\/span>\u00a0too, click on the star and choose us from your favorites.<\/span><\/strong><\/p><\/blockquote>\n

\n

If you want to read more like this article, you can visit our Technology category.<\/a><\/span><\/strong><\/p>\n<\/blockquote>\n

Source<\/a><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

The Eindhoven neurotechnology company is using the proceeds to fund its Empower BP pivotal trial, which tests whether its implantable ARC-IM\u00ae system can treat blood pressure instability after spinal cord injury, while expanding commercial rollout of its already-cleared ARC-EX\u00ae external therapy system. Cash runway now extends to Q1 2028. ONWARD Medical has raised \u20ac40.6 million…<\/p>\n","protected":false},"author":1,"featured_media":722348,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/cdn0.tnwcdn.com\/wp-content\/blogs.dir\/1\/files\/2026\/04\/Onward-Medical.png","fifu_image_alt":"","footnotes":""},"categories":[18],"tags":[],"class_list":["post-722347","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology"],"_links":{"self":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts\/722347","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/comments?post=722347"}],"version-history":[{"count":0,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts\/722347\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/media\/722348"}],"wp:attachment":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/media?parent=722347"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/categories?post=722347"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/tags?post=722347"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}